Core Viewpoint - The company has received approval from the China Securities Regulatory Commission for the full circulation of approximately 182.6 million unlisted shares, allowing them to convert to H-shares and be listed [1] Group 1: Regulatory Approval - The company has completed the filing for the conversion of about 182.6 million unlisted shares into H-shares for full circulation [1] - If the conversion and listing are not completed within 12 months from the date of issuance, the company will need to update its filing materials with the China Securities Regulatory Commission to proceed [1] Group 2: Strategic Development - The company showcased its "Globalization 2.0" strategy at the JPM 2026 conference, outlining its future innovation pipeline and development plans [1] - Over the next five years, the company anticipates more than 40 new clinical research applications to be approved [1] - By 2030, the company expects to have over 20 products launched globally, with 15 of them likely entering the European and American markets [1] Group 3: Product Pipeline and Market Focus - The company plans to commercialize more Antibody-Drug Conjugates (ADCs), bispecific antibodies, and T-cell engagers (TCEs) [1] - The therapeutic areas targeted include oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] Group 4: Financial Performance - As of January 16, the company's stock has increased by 19.63% year-to-date and has risen by 194.18% over the past 250 days [1] - The total market capitalization of the company is HKD 37.1 billion [1]
复宏汉霖(02696.HK)全流通备案落地，全球化2.0战略加速起航